| 07-05-2012 : | HIGHEST EVER INCOME FROM OPERATIONS – RS. 4,278 CRORE, UP 24% YOY ; EBITDA – RS. 893 CRORE, UP 57% YOY; EBITDA MARGINS AT 20.9% FROM 16.5% IN FY 11 ; EXPECT FY13 REVENUE GROWTH AT 20-22% ; BOARD RECOMMENDS HIGHER DIVIDEND OF 300% |
 | The Board of Jubilant Life Sciences Limited, an integrated pharmaceutical and life science industry player met today to approve financial results for the fourth quarter and year ended March 31, 2012. |
| 13-04-2012 : | JUBILANT SEZ AT BHARUCH, INAUGURATED BY SHRI NARENDRA MODI, HON’BLE CHIEF MINISTER OF GUJARAT |
| Jubilant Life Sciences Ltd, an integrated Pharmaceuticals and Life Sciences Company announced today that Shri Narendra Modi, Hon’ble Chief Minister of Gujarat formally inaugurated its new state-of-the-art Special Economic Zone (SEZ) spread over 300 acre in Vilayat Industrial Estate, District Bharuch, Gujarat with an investment of over 500 crores in pursuance of Memorandum of Understanding signed with the Government of Gujarat during the “Vibrant Gujarat” Conference in 2007. |
| 11-04-2012 : | JUBILANT SEZ FACILITY AT BHARUCH, GUJARAT TO BE INAUGURATED BY SHRI NARENDRA MODI, HON’BLE CHIEF MINISTER OF GUJARAT ON APRIL 13, 2012 |
| Jubilant Life Sciences Ltd, an integrated Pharmaceutical and Life Sciences Company and the largest Custom Research & Manufacturing player from India announced today that its new state-of-the-art Special Economic Zone (SEZ) spread over 300 acre in Vilayat Industrial Estate, District Bharuch, Gujarat will be inaugurated by Shri Narendra Modi, Hon’ble Chief Minister of Gujarat on Friday, April 13, 2012. |
| 22-02-2012 : | JUBILANT HOLLISTERSTIER ANNOUNCES MULTI-MILLION DOLLAR AWARD FOR THE MANUFACTURE OF STERILE PARENTERAL PRODUCTS |
| Jubilant HollisterStier, a subsidiary of Jubilant Life Sciences, announced today that its Contract Manufacturing & Services division has recently secured contracts with four innovator life science companies for the commercial manufacturing of sterile parenteral products for sale in the United States and Europe. These agreements will be executed at its Spokane, Washington facility for contract manufacturing of products ranging from liquid to lyophilization presentations, across a variety of patient indications. The total value of these contracts is over US $ 90 million to be delivered over a 5 year period. Commercial transfer to the Jubilant HollisterStier manufacturing facility has commenced for all contracts. |
| 21-02-2012 : | JUBILANT AND MNEMOSYNE PHARMACEUTICALS ANNOUNCE DRUG DISCOVERY COLLABORATION |
| Jubilant Biosys Limited, Bangalore announced today that they have entered into drug discovery collaboration with Mnemosyne Pharmaceutical Inc, Providence, Rhode Island that will seek to identify preclinical candidates in the area of neuropsychiatric diseases. The collaboration will focus on developing subunit selective NMDA receptor modulators (SNRMs) that Mnemosyne has identified. The alliance shall initially span a period of 2 years and may be extended on mutual consent across other therapeutic programs as well. |
| 09-02-2012 : | JUBILANT AND ENDO PHARMACEUTICALS ANNOUNCE SUCCESSFUL DELIVERY OF EARLY MILESTONES IN COLLABORATIVE DISCOVERY PROGRAM |
| Jubilant Biosys Ltd., a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd., announced today that they have achieved an early stage milestone in one of their collaborative programs with Chadds Ford, Pa., USA-based Endo Pharmaceuticals that has nominated a candidate into full development. The novel molecule, targeting cancer, is anticipated to go into clinical trials by late 2012. Jubilant and Endo will continue the collaboration in the development phase as well. |
| 06-02-2012 : | JUBILANT Q3 FY2012 : REVENUE - RS. 1,087CRORE, UP 25% YOY ; RECORDED HIGHEST EVER SALES IN A QUARTER ; EBITDA - RS. 212CRORE, UP 58% YOY; EBITDA MARGINS AT 19.5% AS AGAINST 15.4% IN Q3’FY11 |
| The Board of Jubilant Life Sciences Limited, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company in India met today to approve financial results for the third quarter and nine month period ended December 31, 2011. |
